Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin + nab-paclitaxel + nivolumab with radiotherapy after maximal tumor resection for non-metastatic muscle-invasive bladder cancer
2021-001443-27Phase 2Active
- Sponsor
- Policlinico Gemelli
- Start
- Sep 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel, cisplatin and nivolumab in bladder cancer and transitional cell carcinoma (TCC), sponsored by Policlinico Gemelli. Primary endpoint: One-year disease-free survival rate. Started Sep 2021; status: active.
02
Drugs
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2021-001443-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001443-27.